Immunotherapy in genitourinary cancers: achievements and perspectives
Sign Up to like & getrecommendations! Published in 2021 at "World Journal of Urology"
DOI: 10.1007/s00345-021-03726-1
Abstract: Genito-urinary (GU) malignancies are composed of a heterogeneous group of diseases affecting prostate, kidney, bladder, upper tract, testes, and penis. These cancers depict different biology, natural histories, outcomes and therefore harbor different levels of unmet… read more here.
Keywords: immunotherapy genitourinary; treatment; urology; achievements perspectives ... See more keywords
Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-0890-3
Abstract: Purpose of Review Patient reported outcomes (PROs) are increasingly utilized in cancer drug development, and are of particular importance in genitourinary cancers due to symptom burden, multiple treatment options with similar efficacy, and often prolonged… read more here.
Keywords: drug development; reported outcomes; drug; genitourinary cancers ... See more keywords
Genitourinary cancers—best of ASCO 2020
Sign Up to like & getrecommendations! Published in 2020 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-020-00667-0
Abstract: The aim of this short review is to summarize “clinical practice changing” abstracts about genitourinary cancers from this year’s ASCO Annual Meeting. The phase 3 JAVELIN Bladder 100 trial showed astonishing overall survival (OS) data up… read more here.
Keywords: trial; cancers best; efficacy; best asco ... See more keywords
Current standards and practice changing studies in genitourinary (GU) cancers—a review of studies in localized/early GU cancers
Sign Up to like & getrecommendations! Published in 2022 at "ESMO Open"
DOI: 10.1016/j.esmoop.2022.100432
Abstract: Optimizing treatment of genitourinary cancers in the early-stage setting continues to remain an area of need, given that the development of distant metastases is often the life-limiting factor in the natural history of these cancers.… read more here.
Keywords: genitourinary cancers; current standards; standards practice; changing studies ... See more keywords
Distress and Quality of Life Among Patients with Advanced Genitourinary Cancers.
Sign Up to like & getrecommendations! Published in 2019 at "European urology focus"
DOI: 10.1016/j.euf.2019.10.014
Abstract: Patients with advanced genitourinary cancers face many challenges throughout their disease trajectory, and many will experience clinically relevant psychosocial distress. Certain groups, including female gender, younger age (and older age for suicide), unmarried status, and… read more here.
Keywords: risk; advanced genitourinary; patients advanced; quality life ... See more keywords
Metastatic genitourinary cancer diagnosed by body fluid cytology: clinicopathologic and cytomorphologic correlation.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Society of Cytopathology"
DOI: 10.1016/j.jasc.2016.11.001
Abstract: INTRODUCTION Malignant effusions secondary to genitourinary cancers constitute less than 5% of metastatic malignancies. Because of their rarity, definitive cytodiagnosis may be challenging. Our study aims to examine the incidence of malignant fluids secondary to… read more here.
Keywords: clinicopathologic cytomorphologic; body fluids; genitourinary cancers; metastatic genitourinary ... See more keywords
Improving diagnosis of genitourinary cancers: Biomarker discovery strategies through mass spectrometry-based metabolomics.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.1016/j.jpba.2019.112905
Abstract: The genitourinary oncology field needs integration of results from basic science, epidemiological studies, clinical and translational research to improve the current methods for diagnosis. MS-based metabolomics can be transformative for disease diagnosis and contribute to… read more here.
Keywords: diagnosis; improving diagnosis; based metabolomics; genitourinary cancers ... See more keywords
Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Urology"
DOI: 10.1016/j.urology.2020.10.030
Abstract: Pembrolizumab was recently approved for treatment of cancers with high tumor mutational burden (TMB). We conduct a focused literature review of TMB as a predictive biomarker. TMB quantifies the sum of non-synonymous coding mutations (typically… read more here.
Keywords: tumor mutational; biomarker; genitourinary cancers; tmb ... See more keywords
Rapid screening for genitourinary cancers: mass spectrometry-based metabolic fingerprinting of urine.
Sign Up to like & getrecommendations! Published in 2022 at "Chemical communications"
DOI: 10.1039/d2cc02329f
Abstract: Genitourinary (GU) cancers are among the most common malignant diseases in men. Rapid screening is the key to GU cancer management for early diagnosis and treatment. Urine is a highly accessible specimen type and urine… read more here.
Keywords: screening genitourinary; genitourinary cancers; mass spectrometry; cancers mass ... See more keywords
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Investigation"
DOI: 10.1080/07357907.2022.2136683
Abstract: Abstract Since the approval of the COVID-19 vaccines, their safety and efficacy has been widely demonstrated in patients with cancer. However, there remain patients with reservations regarding vaccination. We aimed to assess genitourinary cancer patients’… read more here.
Keywords: cancer; patients genitourinary; genitourinary cancers; vaccination ... See more keywords
Novel immunotherapy combinations for genitourinary cancers
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1713086
Abstract: ABSTRACT Introduction: Several immune checkpoint inhibitors are FDA-approved for metastatic/advanced RCC and urothelial carcinoma (UC) based on improvements in survival. The dendritic cell vaccine, sipuleucel-T, is also approved for patients with mCRPC, based on a… read more here.
Keywords: immunotherapy combinations; genitourinary cancers; novel immunotherapy; combinations genitourinary ... See more keywords